On September 18, 2025, the public-private partnership (PPP) community came together for the Servier PPP Day at our R&D Institute in Paris-Saclay. On the agenda: interventions, round tables, and workshops to reinforce the impact of such partnerships.
Taking action for collaborative innovation
This event was an opportunity to bring together our community and representatives of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and pharmaceutical companies such as Novo Nordisk. Its theme was dictated by the dual challenge of:
“The Servier PPP Day is a unique opportunity to strengthen our connections and maximize the impact of our collaborations. Our mandate is clear: boldness, assertiveness, selectivity of our projects.“
Nathalie de Préville, Public-Private Partnerships Director, Servier R&D
Public-private partnerships, a powerful lever in accelerating therapeutic innovation
We are convinced that collaboration between public and private players is a powerful lever in accelerating innovation and meeting patient needs. Public-private partnerships (PPPs) are a unique collaborative model, making it possible to pool expertise and resources and share risks to accelerate the discovery and development of new therapeutic solutions. To this end, many Servier employees are engaged in numerous large-scale projects in all our therapeutic areas.
37
To date, 37 PPPs are ongoing at Servier, covering all steps in the value chain of a medicinal product.